Article information
Resumen
Las reacciones adversas por medicamentos suponen un importante problema de salud en los países desarrollados. Explican un 5% de los ingresos hospitalarios y son una de las principales causas de mortalidad. Las manifestaciones neurológicas son de las más frecuentes. En este artículo se revisarán las situaciones catastróficas cerebrovasculares, los síndromes confusionales, la epilepsia por fármacos, la encefalopatía farmacológica estructural, los trastornos neuromusculares por fármacos, los trastornos del movimiento catastróficos por fármacos y las infecciones facilitadas por fármacos.
Palabras clave:
Reacciones adversas a la medicación
Enfermedades del sistema nervioso
Abstract
Drug-induced adverse reactions represent a significant health problem in developed countries. These events cause 5% of hospital admissions and are one of the main causes of mortality. Neurological manifestations are among the most frequent. This article reviews catastrophic cerebrovascular situations and confusional syndromes, as well as epilepsy, structural encephalopathy, neuromuscular disorders, catastrophic movement disorders and infections, all of which can be drug-induced.
Key words:
Drug-induced adverse reactions
Nervous system diseases
Full text is only aviable in PDF
Bibliografía
[1.]
Safety of Medicines. A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action. Medicines Publications and Documentations 2002. [Consulta: 28 abril 2010]. Disponible en: http://www.who.int/medicinedocs/en/d/Jh2992e/#Jh2992e.
[2.]
J.R. Nebeker, P. Barach, M.H. Samore.
Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting.
Ann Intern Med., 140 (2004), pp. 795-801
[3.]
C. Kongkaew, P.R. Noyce, D.M. Ashcroft.
Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.
Ann Pharmacother., 42 (2008), pp. 1017-1025
[4.]
E. Gómez-Ontañón, E. Fernández-Quintana, G. Requena, M.M. García-Saiz, J.N. Boada.
Ausencia de notificación al “sistema español de farmacovigilancia” de las reacciones adversas por fármacos cominicadas en la LII reunión anual de la SEN y publicadas en la revista “Neurología” entre 2000-2001.
Resumen. Neurologia., 16 (2001), pp. 49
[5.]
T.J. Moore, M.R. Cohen, C.D. Furberg.
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.
Arch Intern Med., 167 (2007), pp. 1752-1759
[6.]
C.S. Van der Hooft, J.P. Dieleman, C. Siemes, A.J. Aarnoudse, K.M. Verhamme, B.H. Stricker, et al.
Adverse drug reaction-related hospitalisations: a population-based cohort study.
Pharmacoepidemiol Drug Saf., 17 (2008), pp. 365-371
[7.]
M. Pirmohamed, S. James, S. Meakin, C. Green, A.K. Scott, T.J. Walley, et al.
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients.
BMJ., 329 (2004), pp. 15-19
[8.]
N. Muehlberger, S. Schneeweiss, J. Hasford.
Adverse drug reaction monitoring: cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.
Pharmacoepidemiol Drug Saf., 6 (1997), pp. S71-S77
[9.]
E.E. Roughead, A.L. Gilbert, J.G. Pimrose, L.N. Sansom.
Drug related hospital admisions: a review of Australian studies published 1988-1996.
Med J Aust., 168 (1998), pp. 405-408
[10.]
J. Lazarou, B.H. Pomeranz, P.N. Corey.
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
JAMA., 279 (1998), pp. 1200-1205
[11.]
H.J. Beijer, C.J. De Blaey.
Hospitalizations caused by adverse drug reactions (ADR): a meta-analysis of observational studies.
Pharm World Sci., 24 (2002), pp. 46-54
[12.]
S. Schneeweiss, J. Hasford, M. Gottler, A. Hoffmann, A.K. Riethling, J. Avorn.
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.
Eur J Clin Pharmacol., 58 (2002), pp. 285-291
[13.]
Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier. 2002. [Consulta: 29 abril 2010]. Disponible en: http://www.medicine.ox.ac.uk/bandolier/band101/b101-4.html
[14.]
P. Kanjanarat, A.G. Winterstein, T.E. Johns, R.C. Hatton, R. Gonzalez-Rothi, R. Segal.
Nature of preventable adverse drug events in hospitals: a literature review.
Am J Health Syst Pharm., 60 (2003), pp. 1750-1759
[16.]
J.T. Hanlon, K.E. Schmader, M.J. Koronkowski, M. Weinberger, P.B. Landsman, G.P. Samsa, et al.
Adverse drug events in high risk older outpatients.
J Am Geriatr Soc., 45 (1997), pp. 945-948
[17.]
H. Patel, D. Bell, M. Molokhia, J. Srishanmuganathan, M. Patel, J. Car, et al.
Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005.
BMC Clin Pharmacol., 7 (2007), pp. 9
[18.]
K.M. Cresswell, B. Fernando, B. McKinstry, A. Sheikh.
Adverse drug events in the elderly.
Br Med Bull., 83 (2007), pp. 259-274
[19.]
P.A. Thuermann, R. Windecker, J. Steffen, M. Schaefer, U. Tenter, E. Reese, et al.
Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach.
Drug Saf., 25 (2002), pp. 713-724
[20.]
M. Grenouillet-Delacre, H. Verdoux, N. Moore, F. Haramburu, G. Miremont-Salame, G. Etienne, et al.
Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital.
Intensive Care Med., 33 (2007), pp. 2150-2157
[21.]
J.B. Sexton, E.J. Thomas, R.L. Helmreich.
Error, stress, and teamwork in medicine and aviation: cross sectional surveys.
BMJ., 320 (2000), pp. 745-749
[22.]
E.C. Moser, E.M. Noordijk, F.E. van Leeuwen, C.S. le, J.W. Baars, J. Thomas, et al.
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.
Blood., 107 (2006), pp. 2912-2919
[23.]
E.C. Bluhm, C. Ronckers, R.J. Hayashi, J.P. Neglia, A.C. Mertens, M. Stovall, et al.
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.
Blood., 111 (2008), pp. 4014-4021
[24.]
T.M. Nester, L.S. Hale.
Effectiveness of a pharmacist-acquired medication history in promoting patient safety.
Am J Health Syst Pharm., 59 (2002), pp. 2221-2225
[25.]
V.C. Tam, S.R. Knowles, P.L. Cornish, N. Fine, R. Marchesano, E.E. Etchells.
Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review.
CMAJ., 173 (2005), pp. 510-515
[26.]
J. Gállego, G. Delgado, G. Soriano, J.A. Villanueva.
Fármacos y patología cerebrovascular.
Alteraciones neurológias inducidas por fármacos, pp. 61-75
[27.]
S. Schulman, R.J. Beyth, C. Kearon, M.N. Levine.
Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest., 133 (2008), pp. S257-S298
[28.]
R.G. Hart, O. Benavente, L.A. Pearce.
Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis.
Cerebrovasc Dis., 9 (1999), pp. 215-217
[29.]
M.L. Flaherty, M. Haverbusch, P. Sekar, B. Kissela, D. Kleindorfer, C.J. Moomaw, et al.
Long-term mortality after intracerebral hemorrhage.
Neurology., 66 (2006), pp. 1182-1186
[30.]
M.L. Flaherty, M. Haverbusch, P. Sekar, B.M. Kissela, D. Kleindorfer, C.J. Moomaw, et al.
Location and outcome of anticoagulantassociated intracerebral hemorrhage.
Neurocrit Care., 5 (2006), pp. 197-201
[31.]
M.L. Flaherty, H. Tao, M. Haverbusch, P. Sekar, D. Kleindorfer, B. Kissela, et al.
Warfarin use leads to larger intracerebral hematomas.
Neurology., 71 (2008), pp. 1084-1089
[32.]
M.L. Flaherty, B. Kissela, D. Woo, D. Kleindorfer, K. Alwell, P. Sekar, et al.
The increasing incidence of anticoagulant-associated intracerebral hemorrhage.
Neurology., 68 (2007), pp. 116-121
[33.]
V. Gonugunta, N. Buxton.
Warfarin and chronic subdural haematomas.
Br J Neurosurg., 15 (2001), pp. 514-517
[34.]
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.
Lancet., 343 (1994), pp. 311-322
[35.]
M.L. Simoons, A.P. Maggioni, G. Knatterud, J.D. Leimberger, J.P. De, D.R. Van, et al.
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy.
Lancet., 342 (1993), pp. 1523-1528
[36.]
W. Hacke, G. Donnan, C. Fieschi, M. Kaste, K.R. Von, J.P. Broderick, et al.
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Lancet., 363 (2004), pp. 768-774
[37.]
J. Martí-Fábregas, Y. Bravo, D. Cocho, J.L. Martí-Vilalta, J. Az-Manera, R.L. San, et al.
Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
Cerebrovasc Dis., 23 (2007), pp. 85-90
[38.]
A. Rey, J.L. Martí-Vilalta.
Enfermedad cerebrovascular yatrogénica.
Rev Neurol., 23 (1995), pp. S131-S146
[39.]
W.N. Kernan, C.M. Viscoli, L.M. Brass, J.P. Broderick, T. Brott, E. Feldmann, et al.
Phenylpropanolamine and the risk of hemorrhagic stroke.
N Engl J Med., 343 (2000), pp. 1826-1832
[40.]
C.R. Lake, S. Gallant, E. Masson, P. Miller.
Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports.
Am J Med., 89 (1990), pp. 195-208
[41.]
Phenylpropanolamine Advisory. Food and Drug Administration 2000 November 6. [Consulta: 16 noviembre 2009]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052239.htm.
[42.]
L.B. Morgenstern, C.M. Viscoli, W.N. Kernan, L.M. Brass, J.P. Broderick, E. Feldmann, et al.
Use of Ephedra-containing products and risk for hemorrhagic stroke.
Neurology., 60 (2003), pp. 132-135
[43.]
C. Cantu, A. Arauz, L.M. Murillo-Bonilla, M. López, F. Barinagarrementeria.
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
Stroke., 34 (2003), pp. 1667-1672
[44.]
C. Chen, J. Biller, S.J. Willing, A.M. López.
Ischemic stroke after using over the counter products containing ephedra.
J Neurol Sci., 217 (2004), pp. 55-60
[45.]
L.H. Calabrese, D.W. Dodick, T.J. Schwedt, A.B. Singhal.
Narrative review: reversible cerebral vasoconstriction syndromes.
Ann Intern Med., 146 (2007), pp. 34-44
[46.]
G.K. Call, M.C. Fleming, S. Sealfon, H. Levine, J.P. Kistler, C.M. Fisher.
Reversible cerebral segmental vasoconstriction.
Stroke., 19 (1988), pp. 1159-1170
[47.]
P.Y. Henry, P. Larre, M. Aupy, J.L. Lafforgue, J.M. Orgogozo.
Reversible cerebral arteriopathy associated with the administration of ergot derivatives.
Cephalalgia., 4 (1984), pp. 171-178
[48.]
C.P. Le, F. Woimant, D. Rougemont, M. Sanson, D. Laplane, M. Haguenau, et al.
Angiopathies cerebrales benignes et phenylpropanolamine.
Rev Neurol (Paris)., 144 (1988), pp. 295-300
[49.]
H.G. Raroque Jr., G. Tesfa, P. Purdy.
Postpartum cerebral angiopathy. Is there a role for sympathomimetic drugs?.
Stroke., 24 (1993), pp. 2108-2110
[50.]
L.R. Rogers.
Cerebrovascular complications in cancer patients.
Neurol Clin., 21 (2003), pp. 167-192
[51.]
L. Gugliotta, M.G. Mazzucconi, G. Leone, M. Mattioli-Belmonte, D. Defazio, L. Annino, et al.
Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.
Eur J Haematol., 49 (1992), pp. 63-66
[52.]
C. Urban, W.D. Sager.
Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia.
Eur J Pediatr., 137 (1981), pp. 323-327
[53.]
L.I. Gordon, H.C. Kwaan.
Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient.
Semin Thromb Hemost., 25 (1999), pp. 217-221
[54.]
H.C. Kwaan, L.I. Gordon.
Thrombotic microangiopathy in the cancer patient.
Acta Haematol., 106 (2001), pp. 52-56
[55.]
R.A. Lenz, J. Saver.
Venous sinus thrombosis in a patient taking thalidomide.
Cerebrovasc Dis., 18 (2004), pp. 175-177
[56.]
M. Hazarika, E. Rock, G. Williams, R. Dagher, R. Sridhara, B. Booth, et al.
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Oncologist., 13 (2008), pp. 1120-1127
[57.]
J. Masjuan, J. Pardo, J.M. Callejo, M.T. Andrés, K. Alwell, et al.
Tamoxifen: a new risk factor for cerebral sinus thrombosis.
Neurology., 62 (2004), pp. 334-335
[58.]
G. Akdal, B. Donmez, H. Cakmakci, G.G. Yener.
A case with cerebral thrombosis receiving tamoxifen treatment.
Eur J Neurol., 8 (2001), pp. 723-724
[60.]
P.F. Finelli, P.K. Schauer.
Cerebral sinus thrombosis with tamoxifen.
Neurology., 56 (2001), pp. 1113-1114
[61.]
S. Schachter, R. Freeman.
Transient ischemic attack and adriamycin cardiomyopathy.
Neurology., 32 (1982), pp. 1380-1381
[62.]
P.F. Finelli, M.D. Carley.
Cerebral venous thrombosis associated with epoetin alpha therapy.
Arch Neurol., 57 (2000), pp. 260-262
[63.]
J. Francis, D. Martin, W.N. Kapoor.
A prospective study of delirium in hospitalized elderly.
JAMA., 263 (1990), pp. 1097-1101
[64.]
E.W. Ely, S. Gautam, R. Margolin, J. Francis, L. May, T. Speroff, et al.
The impact of delirium in the intensive care unit on hospital length of stay.
Intensive Care Med., 27 (2001), pp. 1892-1900
[65.]
E.W. Ely, A. Shintani, B. Truman, T. Speroff, S.M. Gordon, F.E. Harrell Jr., et al.
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.
JAMA., 291 (2004), pp. 1753-1762
[66.]
S. Ouimet, B.P. Kavanagh, S.B. Gottfried, Y. Skrobik.
Incidence, risk factors and consequences of ICU delirium.
Intensive Care Med., 33 (2007), pp. 66-73
[67.]
M.A. Rudberg, P. Pompei, M.D. Foreman, R.E. Ross, C.K. Cassel.
The natural history of delirium in older hospitalized patients: a syndrome of heterogeneity.
Age Ageing., 26 (1997), pp. 169-174
[68.]
S.K. Inouye.
The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients.
Am J Med., 97 (1994), pp. 278-288
[69.]
A.R. Moore, S.T. O’Keeffe.
Drug-induced cognitive impairment in the elderly.
Drugs Aging., 15 (1999), pp. 15-28
[71.]
E. Perucca.
Seizures provoked by antepileptic drugs and by other medications.
Neurologia., 16 (2001), pp. S43-51
[72.]
I. Osorio, R.C. Reed.
Treatment of refractory generalized tonicclonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin.
Epilepsia, 30 (1989), pp. 464-471
[73.]
L.L. Levy, G.M. Fenichel.
Diphenylhydantoin activated seizures.
Neurology., 15 (1965), pp. 716-722
[74.]
H. Patel, J.U. Crichton.
The neurologic hazards of diphenylhydantoin in childhood.
J Pediatr., 73 (1968), pp. 676-684
[75.]
N. Stilman, J.C. Masdeu.
Incidence of seizures with phenytoin toxicity.
Neurology., 35 (1985), pp. 1769-1772
[76.]
P. Marioni, F. Galletti, M. Brinciotti, A. Pelliccia.
Stato di male non-convulsivo in rapporto a intossicazione da fenobarbital.
Minerva Pediatr., 39 (1987), pp. 865-868
[77.]
D.F. Weaver, P. Camfield, A. Fraser.
Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes.
Neurology., 38 (1988), pp. 755-759
[78.]
P. Thomas, L. Valton, P. Genton.
Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.
Brain., (2006), pp. 129
[79.]
H. Jick, B.J. Dinan, J.R. Hunter, A. Stergachis, A. Ronning, D.R. Perera, et al.
Tricyclic antidepressants and convulsions.
J Clin Psychopharmacol., 3 (1983), pp. 182-185
[81.]
G. Calandra, E. Lydick, J. Carrigan, L. Weiss, H. Guess.
Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.
Am J Med., 84 (1988), pp. 911-918
[82.]
R.H. Eng, A.N. Munsif, B.G. Yangco, S.M. Smith, H. Chmel.
Seizure propensity with imipenem.
Arch Intern Med., 149 (1989), pp. 1881-1883
[83.]
R.C. Owens Jr., P.G. Ambrose.
Antimicrobial safety: focus on fluoroquinolones.
Clin Infect Dis., 41 (2005), pp. S144-S157
[84.]
K.M. Chow, C.C. Szeto, A.C. Hui, T.Y. Wong, P.K. Li.
Retrospective review of neurotoxicity induced by cefepime and ceftazidime.
Pharmacotherapy., 23 (2003), pp. 369-373
[85.]
A. Saurina, M. Vera, M. Pou, P.J. López, A. Darnell, J.M. Campistol, et al.
Estatus epiléptico no convulsivo secundario a cefepima a dosis ajustadas en enfermos con insuficiencia renal crónica.
Nefrología., 20 (2000), pp. 554-558
[86.]
A.D. Klion, J. Kallsen, C.T. Cowl, W.M. Nauseef.
Ceftazidime-related nonconvulsive status epilepticus.
Arch Intern Med., 154 (1994), pp. 586-589
[87.]
V.K. Wong, H.T. Wright Jr., L.A. Ross, W.H. Mason, C.B. Inderlied, K.S. Kim.
Imipenem/cilastatin treatment of bacterial meningitis in children.
Pediatr Infect Dis J., 10 (1991), pp. 122-125
[88.]
V. Tajender, J. Saluja.
INH induced status epilepticus: response to pyridoxine.
Indian J Chest Dis Allied Sci., 48 (2006), pp. 205-206
[89.]
N. Steeghs, F.E. de Jongh, P.A. Sillevis Smitt, M.J. van den Bent.
Cisplatin-induced encephalopathy and seizures.
Anticancer Drugs., 14 (2003), pp. 443-446
[90.]
S. Kilickap, M. Cakar, I.K. Onal, A. Tufan, H. Akoglu, S. Aksoy, et al.
Nonconvulsive status epilepticus due to ifosfamide.
Ann Pharmacother., 40 (2006), pp. 332-335
[91.]
D.H. Lowenstein.
Status epilepticus: an overview of the clinical problem.
Epilepsia, 40 (1999), pp. S3-8
[92.]
J. Hinchey, C. Chaves, B. Appignani, J. Breen, L. Pao, A. Wang, et al.
A reversible posterior leukoencephalopathy syndrome.
N Engl J Med., 334 (1996), pp. 494-500
[93.]
W.O. Bechstein.
Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Transpl Int., 13 (2000), pp. 313-326
[94.]
E.F. Wijdicks.
Neurotoxicity of immunosuppressive drugs.
Liver Transpl., 7 (2001), pp. 937-942
[95.]
A.A. Marinas, G. Gutiérrez-Gutiérrez, G.N. Carrera.
Encefalopatía posterior reversible producida por tacrólimus.
Neurología., 20 (2005), pp. 379
[96.]
L.M. Romano, R.P. de, P. Ioli, E. García-Saiz.
Síndrome de leucoencefalopatía posterior reversible por cisplatino: presentación de un caso.
Rev Neurol., 41 (2005), pp. 573-574
[97.]
I. Mathy, M. Gille, R.F. Van, J. Delbecq, A. Depre.
Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.
Acta Neurol Belg., 98 (1998), pp. 347-351
[98.]
M. Alaña, M. Navarro, J. Pascual.
Leucoencefalopatía posterior reversible: la lista de culpables aumenta.
Neurología., 23 (2008), pp. 137-138
[99.]
O. Merimsky, M. Inbar, I. Reider-Groswasser, M. Scharf, S. Chaitchik.
Ifosfamide-related acute encephalopathy: clinical and radiological aspects.
Eur J Cancer., 27 (1991), pp. 1188-1189
[100.]
S.R. Plotkin, P.Y. Wen.
Neurologic complications of cancer therapy.
Neurol Clin., 21 (2003), pp. 279-318
[101.]
W. Kuker, P. Bader, U. Herrlinger, S. Heckl, T. Nagele.
Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI.
J Neurooncol., 73 (2005), pp. 47-49
[102.]
Y.S. Yim, D.H. Mahoney Jr., D.G. Oshman.
Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia.
Cancer., 67 (1991), pp. 2058-2061
[103.]
M. Linnebank, S. Moskau, A. Jurgens, M. Simon, A. Semmler, K. Orlopp, et al.
Association of genetic variants of methionine metabolism with MTX-induced CNS white matter changes in patients with primary central nervous system lymphoma.
Neuro Oncol., 11 (2009), pp. 2-8
[104.]
M. Linnebank, S. Malessa, S. Moskau, A. Semmler, H. Pels, T. Klockgether, et al.
Acute methotrexate-induced encephalopathy: causal relation to homozygous allelic state for MTR c.2756A>G (D919G)?.
J Chemother., 19 (2007), pp. 455-457
[105.]
M. Linnebank, H. Pels, N. Kleczar, S. Farmand, K. Fliessbach, H. Urbach, et al.
MTX-induced white matter changes are associated with polymorphisms of methionine metabolism.
Neurology., 64 (2005), pp. 912-913
[106.]
S.G. Worthley, J.D. McNeil.
Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis.
J Rheumatol., 22 (1995), pp. 335-337
[107.]
J.M. Baehring, R.K. Fulbright.
Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
J Neurol Neurosurg Psychiatry., 79 (2008), pp. 535-539
[108.]
R.B. Diasio, T.L. Beavers, J.T. Carpenter.
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.
J Clin Invest., 81 (1988), pp. 47-51
[109.]
C.H. Takimoto, Z.H. Lu, R. Zhang, M.D. Liang, L.V. Larson, L.R. Cantilena Jr., et al.
Severe neurotoxicity following 5-fluorouracilbased chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
Clin Cancer Res., 2 (1996), pp. 477-481
[110.]
B. Niemann, C. Rochlitz, R. Herrmann, M. Pless.
Toxic encephalopathy induced by capecitabine.
Oncology., 66 (2004), pp. 331-335
[111.]
W.R. Shapiro, S.B. Green, P.C. Burger, R.G. Selker, J.C. VanGilder, J.T. Robertson, et al.
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
J Neurosurg., 76 (1992), pp. 772-781
[112.]
W.R. Shapiro, S.B. Green.
Reevaluating the efficacy of intra-arterial BCNU.
J Neurosurg., 66 (1987), pp. 313-315
[113.]
J. Watterson, I. Toogood, M. Nieder, M. Morse, S. Frierdich, Y. Lee, et al.
Excessive spinal cord toxicity from intensive central nervous system-directed therapies.
Cancer., 74 (1994), pp. 3034-3041
[114.]
P. Counsel, M. Khangure.
Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings.
Clin Radiol., 62 (2007), pp. 172-176
[115.]
C.L. Chou, Y.H. Chen, T. Chau, S.H. Lin.
Acquired bartter-like syndrome associated with gentamicin administration.
Am J Med Sci., 329 (2005), pp. 144-149
[116.]
C.J. Shiah, D.M. Tsai, S.T. Liao, C.P. Siauw, L.S. Lee.
Acute muscular paralysis in an adult with subclinical Bartter's syndrome associated with gentamicin administration.
Am J Kidney Dis., 24 (1994), pp. 932-935
[117.]
E. Gutiérrez-Rivas.
Medicación concomitante en la Miastenia Gravis.
Mito y realidad., (2003),
[118.]
J. Howard.
Toxic Neuromuscular Transmission Disorders.
Myasthenia Gravis and Related Disorders, pp. 327-354
[119.]
A. Martínez-Arizala, S.M. Sobol, G.E. McCarty, B.R. Nichols, L. Rakita.
Amiodarone neuropathy.
Neurology., 33 (1983), pp. 643-645
[120.]
J.R. Wilson, R.A. Conwit, B.H. Eidelman, T. Starzl, K. Abu-Elmagd.
Sensorimotor neuropathy resembling CIDP in patients receiving FK506.
Muscle Nerve., 17 (1994), pp. 528-532
[121.]
D. Rodríguez-Gómez, A. Rodríguez-Rodríguez, O. Pérez-Carral, M. Lustres-Pérez, M.C. Cid-Rodríguez.
Polineuropatía desmielinizante crónica secundaria al tratamiento con tacrólimus.
Rev Neurol., 46 (2008), pp. 189-190
[122.]
G. Laham, A. Vilches, L. Jost, L. Jost, M. Nogues.
Polineuropatía desmielinizante periférica aguda e insuficiencia renal aguda secundaria a la administración de FK 506.
Medicina (B. Aires)., 61 (2001), pp. 445-446
[123.]
L. Holmberg, G. Boman, L.E. Bottiger, B. Eriksson, R. Spross, A. Wessling.
Adverse reactions to nitrofurantoin. Analysis of 921 reports.
Am J Med., 69 (1980), pp. 733-738
[124.]
J.F. Toole, M.L. Parrish.
Nitrofurantoin polyneuropathy.
Neurology., 23 (1973), pp. 554-559
[125.]
R. Raschetti, M. Maggini, P. Popoli, B. Caffari, C.R. Da, F. Menniti-Ippolito, et al.
Gangliosides and Guillain-Barré syndrome.
J Clin Epidemiol., 48 (1995), pp. 1399-1405
[126.]
E. Díez-Tejedor, E. Gutiérrez-Rivas, A. Gil-Peralta.
Gangliosides and Guillain-Barré syndrome: the Spanish data.
Neuroepidemiology., 12 (1993), pp. 251-256
[127.]
E. Granieri, I. Casetta, V. Govoni, M.R. Tola, E. Paolino, W.A. Rocca.
Ganglioside therapy and Guillain-Barré syndrome. A historical cohort study in Ferrara, Italy, fails to demonstrate an association.
Neuroepidemiology., 10 (1991), pp. 161-169
[128.]
P. Haber, F. DeStefano, F.J. Angulo, J. Iskander, S.V. Shadomy, E. Weintraub, et al.
Guillain-Barré syndrome following influenza vaccination.
JAMA., 292 (2004), pp. 2478-2481
[129.]
P. Haber, J. Sejvar, Y. Mikaeloff, F. DeStefano.
Vaccines and Guillain-Barré syndrome.
Drug Saf., 32 (2009), pp. 309-323
[130.]
S. Silburn, E. McIvor, A. McEntegart, H. Wilson.
Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
Ann Rheum Dis., 67 (2008), pp. 575-576
[131.]
N.T. Johnson, S.W. Crawford, M. Sargur.
Acute acquired demyelinating polyneuropathy with respiratory failure following highdose systemic cytosine arabinoside and marrow transplantation.
Bone Marrow Transplant., 2 (1987), pp. 203-207
[132.]
H. Openshaw, N.E. Slatkin, A.S. Stein, D.R. Hinton, S.J. Forman.
Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia.
Cancer., 78 (1996), pp. 1899-1905
[133.]
W.L. Osborne, T.L. Holyoake, I.G. McQuaker, A.N. Parker.
Fatal peripheral neuropathy following FLA chemotherapy.
Clin Lab Haematol., 26 (2004), pp. 295-296
[134.]
S.S. Moudgil, J.E. Riggs.
Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy.
Ann Pharmacother., 34 (2000), pp. 1136-1138
[135.]
W.D. Graf, P.F. Chance, M.W. Lensch, L.J. Eng, H.P. Lipe, T.D. Bird.
Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.
Cancer., 77 (1996), pp. 1356-1362
[136.]
N. Bakshi, R.A. Maselli, S.M. Gospe Jr., W.G. Ellis, C. McDonald, R.N. Mandler.
Fulminant demyelinating neuropathy mimicking cerebral death.
Muscle Nerve., 20 (1997), pp. 1595-1597
[137.]
A.M. Orejana-García, J. Pascual-Huerta, A. Pérez-Melero.
Charcot-Marie-Tooth disease and vincristine.
J Am Podiatr Med Assoc., 93 (2003), pp. 229-233
[138.]
G. Hildebrandt, E. Holler, M. Woenkhaus, G. Quarch, A. Reichle, B. Schalke, et al.
Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
Ann Oncol., 11 (2000), pp. 743-747
[139.]
A.A. Amato.
Endocrine Myopathies and Toxic Myopathies.
Neuromuscular Function and Disease, pp. 1399-1427
[140.]
R.J. Walsh, A.A. Amato.
Toxic myopathies.
Neurol Clin., 23 (2005), pp. 397-428
[141.]
K. Wilbur, M. Makowsky.
Colchicine myotoxicity: case reports and literature review.
Pharmacotherapy., 24 (2004), pp. 1784-1792
[142.]
M. Justiniano, S. Dold, L.R. Espinoza.
Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.
J Clin Rheumatol., 13 (2007), pp. 266-268
[143.]
W.C. Hsu, W.H. Chen, M.T. Chang, H.C. Chiu.
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Clin Neuropharmacol., 25 (2002), pp. 266-268
[144.]
G. Alayli, K. Cengiz, F. Canturk, D. Durmus, Y. Akyol, E.B. Menekse.
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
Ann Pharmacother., 39 (2005), pp. 1358-1361
[145.]
A.J. Lee, D.S. Maddix.
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Ann Pharmacother., 35 (2001), pp. 26-31
[146.]
L. Francis, E. Bonilla, E. Soforo, H. Neupane, H. Nakhla, C. Fuller, et al.
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin.
Clin Rheumatol., 27 (2008), pp. 129-131
[147.]
A.K. Siddiqui, S.I. Huberfeld, K.M. Weidenheim, K.R. Einberg, L.S. Efferen.
Hydroxychloroquine-induced toxic myopathy causing respiratory failure.
Chest., 131 (2007), pp. 588-590
[148.]
P. Seguin, C. Camus, J.P. Leroy, T.Y. Le, I. Jouannic, R. Thomas.
Respiratory failure associated with hydroxychloroquine neuromyopathy.
Eur Neurol., 35 (1995), pp. 236-237
[149.]
J.P. Hanna, M.L. Ramundo.
Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children.
Neurology., 50 (1998), pp. 301-303
[150.]
I. Tein, S. Dimauro, L.P. Rowland.
Myoglobinuria.
Myopathies, pp. 553-593
[151.]
Pestronk A. Malignant Hyperthermia Syndromes. Neuromuscular Disease Center. [Consulta: 28 abril 2010]. Disponible en: http://neuromuscular.wustl.edu/msys/myoglob.html#mhgeneral
[152.]
J. Delay, P. Pichot, T. Lemperiere, B. Elissalde, F. Peigne.
Un neuroleptique majeur non phenothiazinique et non reserpinique l’haloperidol dans le traitement des psychoses.
Ann Med Psychol (Paris)., 118 (1959), pp. 145-152
[153.]
F.J. Ayd Jr..
Fatal hyperpyrexia during chlorpromazine therapy.
J Clin Exp Psychopathol., 17 (1956), pp. 189-192
[154.]
P.E. Keck Jr., H.G. Pope Jr., B.M. Cohen, S.L. McElroy, A.A. Nierenberg.
Risk factors for neuroleptic malignant syndrome. A casecontrol study.
Arch Gen Psychiatry., 46 (1989), pp. 914-918
[155.]
P.I. Rosebush, T.D. Stewart, A.J. Gelenberg.
Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients.
J Clin Psychiatry., 50 (1989), pp. 295-298
[156.]
S.N. Caroff, S.C. Mann.
Neuroleptic malignant syndrome.
Med Clin North Am., 77 (1993), pp. 185-202
[157.]
J.L. Levenson.
Neuroleptic malignant syndrome.
Am J Psychiatry., 142 (1985), pp. 1137-1145
[158.]
P.I. Rosebush, T. Stewart, M.F. Mazurek.
The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?.
Br J Psychiatry., 159 (1991), pp. 709-712
[159.]
P.I. Rosebush, M.F. Mazurek.
Bromocriptine and neuroleptic malignant syndrome.
J Clin Psychiatry., 52 (1991), pp. 41-42
[160.]
M. Fink.
Convulsive therapy: a review of the first 55 years.
J Affect Disord., 63 (2001), pp. 1-15
[161.]
F. Ozer, H. Meral, B. Aydin, L. Hanoglu, T. Aydemir, T. Oral.
Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome.
J ECT., 21 (2005), pp. 125-127
[162.]
Y. Mizuno, H. Takubo, E. Mizuta, S. Kuno.
Malignant syndrome in Parkinson's disease: concept and review of the literature.
Parkinsonism Relat Disord., 9 (2003), pp. S3-9
[163.]
L.J. Meagher, D. McKay, G.K. Herkes, M. Needham.
Parkinsonismhyperpyrexia syndrome: the role of electroconvulsive therapy.
J Clin Neurosci., 13 (2006), pp. 857-859
[164.]
E. Hadad, A.A. Weinbroum, R. Ben-Abraham.
Drug-induced hyperthermia and muscle rigidity: a practical approach.
Eur J Emerg Med., 10 (2003), pp. 149-154
[165.]
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 200517; 352: 1112-20.
[167.]
J.A. Flaherty, H.W. Lahmeyer.
Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment.
Am J Psychiatry., 135 (1978), pp. 1414-1415
[168.]
H. Newton-John.
Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic.
BMJ., 297 (1988), pp. 964-965
[169.]
E. Pinczower, D.H. Rice.
Drug-induced dystonia and airway obstruction in a patient with nasal packing.
Otolaryngol Head Neck Surg., 103 (1990), pp. 658-659
[170.]
G.A. Barclay, W. Giridharan, E. Guntis, Y. Karagama, R.S. Williams.
Upper airway obstruction resulting from an antiemetic.
Int J Clin Pract., 56 (2002), pp. 814-815
[171.]
E. Barach, L.M. Dubin, M.C. Tomlanovich, S. Kottamasu.
Dystonia presenting as upper airway obstruction.
J Emerg Med., 7 (1989), pp. 237-240
[172.]
A.C. Thompson, L.G. McClymont.
Acute upper airway obstruction due to supraglottic dystonia.
BMJ., 297 (1988), pp. 1469-1470
[173.]
A.M. Lydon, J.F. Boylan.
Reversibility of parkinsonism-induced acute upper airway obstruction by benztropine therapy.
Anesth Analg., 87 (1998), pp. 975-976
[174.]
K.R. Carson, D. Focosi, E.O. Major, M. Petrini, E.A. Richey, D.P. West, et al.
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Lancet Oncol., 10 (2009), pp. 816-824
[175.]
Rituxan (rituximab) - PML. US Food and Drug Administration. [Consulta: 29 abril 2010]. Disponible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm187791.htm
[176.]
B.K. Kleinschmidt-DeMasters, K.L. Tyler.
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
N Engl J Med., 353 (2005), pp. 369-374
[177.]
A. Langer-Gould, S.W. Atlas, A.J. Green, A.W. Bollen, D. Pelletier.
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
N Engl J Med., 353 (2005), pp. 375-381
[178.]
A.G. Van, R.M. Van, R. Sciot, B. Dubois, S. Vermeire, M. Noman, et al.
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
N Engl J Med., 353 (2005), pp. 362-368
[179.]
Information on Natalizumab (marketed as Tysabri). Food and Drug Administration 2010 February 5. [Consulta: 28 abril 2010]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm
[180.]
Ficha técnica micofenolato mofetilo. Agencia Europea del Medicamento 2009. [Consulta: 28 abril 2010]. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cellcept/emea-combined-h82es.pdf
[181.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med., 345 (2001), pp. 1098-1104
Copyright © 2010. Sociedad Española de Neurología
